C4T reported Q4 FY2025 revenue from collaboration agreements of USD 11.0 million, up 112.7%, and FY2025 revenue of USD 35.9 million. Q4 R&D expense was USD 25.0 million and Q4 G&A expense was USD 9.2 million. C4T posted a Q4 net loss of USD 20.5 million, with net loss per share of USD 0.18, and a FY2025 net loss of USD 105.0 million, with net loss per share of USD 1.27. Cash, cash equivalents and marketable securities totaled USD 297.1 million at December 31, 2025, and C4T said this is expected to fund its operating plan to the end of 2028. On the business side, C4T said the first patient was dosed in February 2026 in the Phase 2 MOMENTUM trial of cemsidomide plus dexamethasone in fourth line or later multiple myeloma, with enrollment of about 100 patients expected to complete in Q1 2027; the trial is designed for potential accelerated approval and uses a recommended Phase 2 dose of 100 µg. The company also said it remains on track to initiate a Phase 1b trial of cemsidomide in combination with Pfizer-supplied elranatamab in Q2 2026. Separately, C4T reported it earned a USD 2.0 million milestone payment from Biogen in January 2026 related to BIIB145, a BTK degrader that entered clinical development for autoimmune diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.
Comments